Literature DB >> 2053593

Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg.

T Kajita1, T E Hugli.   

Abstract

The anaphylatoxin C3a (125I-HC3a) is extensively degraded when exposed to isolated rat mast cells (RMC). Degradation occurs without prior stimulation of these cells. The protease responsible for C3a degradation has been identified as chymase. Mixed peritoneal cells, containing equal numbers of mast cells compared with incubates containing more highly purified RMC, promoted less degradation of the C3a molecule than did the purified RMC. These variable levels of spontaneous activation (ie, chymase release) of RMC in vitro were concluded to be a function of the cellular handling and isolation procedures. No degradation occurred when low levels of 125I-HC3ades Arg (10(-8) mol/l [molar]) were introduced in the peritoneum of a rat, unless the mast cells were stimulated by prior introduction of specific activators. Evidence that the enzyme being released in the peritoneal cavity of rats was chymase was provided both by its appearance after adding specific mast cell activators (ie, compound 48/80 and anti-IgE [gamma E immunoglobulin]) and by inhibition with chymostatin. Because 125I-HC3ades Arg at low levels (10(-8) mol/l) was not degraded in the rat peritoneum, expression of chymase by the rat mast cells could be monitored in situ during mast cell stimulation. 125I-HC3ades Arg was rapidly converted (in 2 to 5 minutes) to smaller fragments in the peritoneal cavity of the rat after either 10 micrograms of compound 48/80 or anti-IgE was injected. Introduction of higher levels of HC3a or HC3ades Arg (2.5 to 5.0 x 10(-6) mol/l) to the peritoneal cavity of the rat stimulated both chymase release and HC3a degradation without other mast cell activators being present. HC3ades Arg was equally as effective in vivo as HC3a in stimulating the rat peritoneal mast cell to release chymase. It was concluded that the mechanism of RMC activation by C3a (C3ades Arg) was nonspecific and similar to the process by which polyamines and polycations stimulate mast cells, as C3a is a highly cationic molecule. The fact that C3a may in turn be destroyed in minutes by the recruited protease (chymase) defines a potentially important physiologic control mechanism. This cellular control process, demonstrated here for rat mast cells, may function in other animals, including man, for regulating tissue levels of factors such as the anaphylatoxins that are potentially capable of mast cell activation through nonspecific (polycationic) mechanisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2053593      PMCID: PMC1886399     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Histamine release by compounds of simple chemical structure.

Authors:  W D PATON
Journal:  Pharmacol Rev       Date:  1957-06       Impact factor: 25.468

2.  Identification of a chymotrypsin-like proteinase in human mast cells.

Authors:  N M Schechter; J K Choi; D A Slavin; D T Deresienski; S Sayama; G Dong; R M Lavker; D Proud; G S Lazarus
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Two types of human mast cells that have distinct neutral protease compositions.

Authors:  A A Irani; N M Schechter; S S Craig; G DeBlois; L B Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

5.  Low density lipoprotein degradation by secretory granules of rat mast cells. Sequential degradation of apolipoprotein B by granule chymase and carboxypeptidase A.

Authors:  J O Kokkonen; M Vartiainen; P T Kovanen
Journal:  J Biol Chem       Date:  1986-12-05       Impact factor: 5.157

6.  Low density lipoprotein degradation by rat mast cells. Demonstration of extracellular proteolysis caused by mast cell granules.

Authors:  J O Kokkonen; P T Kovanen
Journal:  J Biol Chem       Date:  1985-11-25       Impact factor: 5.157

7.  Platelet-serotonin release by C3a and C5a: two independent pathways of activation.

Authors:  S Meuer; U Ecker; U Hadding; D Bitter-Suermann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

8.  Improved method for direct counting of basophil leucocytes.

Authors:  J R Cooper; C N Cruickshank
Journal:  J Clin Pathol       Date:  1966-07       Impact factor: 3.411

9.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

10.  Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man.

Authors:  I H Lepow; K Willms-Kretschmer; R A Patrick; F S Rosen
Journal:  Am J Pathol       Date:  1970-10       Impact factor: 4.307

View more
  4 in total

1.  Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.

Authors:  Beatrix Schäfer; Adrian M Piliponsky; Tatsuya Oka; Chang Ho Song; Norma P Gerard; Craig Gerard; Mindy Tsai; Janet Kalesnikoff; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2012-06-22       Impact factor: 10.793

Review 2.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 3.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

4.  Mast cell degranulation induced by type 1 fimbriated Escherichia coli in mice.

Authors:  R Malaviya; E Ross; B A Jakschik; S N Abraham
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.